• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

How Pharmaceutical Companies can Capture Maximum Value from M&A: Infiniti Research Reveals Key Considerations for Pharma M&A Success

Share:

March 30, 2020

Infiniti Research is a leading provider of market intelligence services to businesses around the globe. For over 15 years, Infiniti has been helping companies across industries to identify key market challenges and strategize to meet the changing market demands. In their recent article, experts at Infiniti Research give comprehensive insights on how companies can leverage maximum value from pharma M&A deals.

Why partner with us?

The pharmaceutical industry is one of the major sectors that is actively involved in huge mergers and acquisition (M&A) deals, both in terms of numbers of deals and the amount of money spent. Most companies in the sector, especially the big pharma, consider pharma M&A as a major factor to bolster innovation and overall growth. Pharma M&A has become a common practice for companies that have non-diverse pipelines or have top revenue drugs that are nearing patent expiration and subsequent generic erosion. According to industry experts at Infiniti Research, some of the key reasons why companies favor pharma M&A include critical size requirements across various market segments, bundling of sub-critical businesses, and to capture annual cost synergies by scaling up. For more insights on key considerations for successful pharma M&A.

Read more

Source: Olean Times Herald

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Procyrion Raises $30M to Support Clinical Trials of its Percutaneous Blood Pump DeviceProcyrion Raises $30M to Support Clinical Trials of its Percutaneous Blood Pump Device
  • MRI Interventions, Inc. Closes $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital ManagementMRI Interventions, Inc. Closes $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management
  • Rafarma Finalizes Acquisition of Laskavy Patents, Prepared as Global Markets ResetRafarma Finalizes Acquisition of Laskavy Patents, Prepared as Global Markets Reset
  • PFIZER COMPLETES ACQUISITION OF THERACHONPFIZER COMPLETES ACQUISITION OF THERACHON
  • Personal Training App’s $4.5M Aound Headlined By A-Rod, 24 Hour Fitness Founder, Corazon CapitalPersonal Training App’s $4.5M Aound Headlined By A-Rod, 24 Hour Fitness Founder, Corazon Capital
  • Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.
  • Athenahealth Launches COVID-19 Dashboards Tracking Lab Test Orders & High-Risk PatientsAthenahealth Launches COVID-19 Dashboards Tracking Lab Test Orders & High-Risk Patients
  • New Threat Intelligence Platform Is Tailored For Clinical And C-Suite LeadersNew Threat Intelligence Platform Is Tailored For Clinical And C-Suite Leaders

Trending This Week

  • Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
  • GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies GroupGelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security Market
  • Life Launches AI Clinical Trial Matching Assistant for Cancer
  • 79% of Healthcare Execs Believe Most Drug Diversion Goes Undetected
  • Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine
  • FDA Releases Updated Final Guidance for its Breakthrough Devices Program

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications